沙利度胺是什麼？

沙利度胺是一種鎮靜催眠和多發性骨髓瘤的藥物。這種藥是兔和包括人類的靈長類動物的烈性 teratogen：嚴重的出生缺陷可能會導致在懷孕期間服用該藥物。

在一些國家出售胺 1957 直到 1961 它何時退出市場後被發現是什麼被稱為"最大的近代醫學悲劇之一"出生缺陷的原因, 從世界各地。它不知道確切的藥物有多少世界各地受害者已，雖然估計為 20000 的範圍由 10000。

自那時以來已發現胺是寶貴的治療，大量的醫療條件，它被明再次在一些國家，儘管其使用仍有爭議。沙利度胺悲劇導致更加嚴格測試正在和所需的藥物農藥之前他們可發牌。

進一步閱讀

這篇文章是創作共用署名-相同方式共用授權許可。它使用材料從維琪百科上"反應停"適應所有材料用從維琪百科的文章是創新的知識共用署名-相同方式共用許可證的條款下提供。維琪百科 ® 本身是維琪媒體基金公司的註冊的商標

Recent Thalidomide News

NEJM publishes results from Celgene’s REVLIMID phase III studies on MMCelgene International Sàrl, a subsidiary of Celgene Corporation, today announced that results from three phase III studies evaluating the use of continuous REVLIMID(lenalidomide) treatment in newly di...

Lenalidomide improves overall survival for patients with multiple myelomaData from the first large U.S. study assessing the effectiveness of long-term "maintenance" therapy with lenalidomide for patients with multiple myeloma show that the drug significantly improves the t...

Researchers discover connection between early humans and Neanderthals' genomeA striking discovery in the study of human genetics was the focus of the most-visited press release posted on EurekAlert! in 2011. Researchers found that part of the non-African human X chromosome cam...

Enrollment complete in Onyx Phase 3 ASPIRE trial for relapsed multiple myelomaOnyx Pharmaceuticals, Inc. today announced that it has reached the target enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide...

Cereblon protein now holds hope in fight against multiple myelomaResearch on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against multiple myeloma, say Mayo Clinic researchers who presented res...